The Clinical Research of Intranasal Dexmedetomidine Used in Plastic Surgery of Children

NCT ID: NCT02222636

Last Updated: 2014-08-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to explore the optimal protocol for dexmedetomidine used in children during perioperative period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

The Efficacy and Safety of Intranasal Dexmedetomidine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1,Normal saline,1 milliliter

Patients will be assigned to receive intranasal normal saline 1 milliliter

Group Type PLACEBO_COMPARATOR

Normal saline,1 milliliter

Intervention Type DRUG

Normal saline,1 milliliter, 20 minutes before anaesthetic induction

Anesthesia induction, 8% sevoflurane

Intervention Type DRUG

Inhalation induction with 8% sevoflurane

Anesthesia maintenance, 2%~3% sevoflurane,fentanyl

Intervention Type DRUG

2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion

Group 2,dexmedetomidine 1μg.kg-1,1 milliliter

Patients will be assigned to receive intranasal dexmedetomidine( 1μg.kg-1) 1 milliliter

Group Type EXPERIMENTAL

Dexmedetomidine 1 μg.kg-1,1 milliliter

Intervention Type DRUG

Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction

Anesthesia induction, 8% sevoflurane

Intervention Type DRUG

Inhalation induction with 8% sevoflurane

Anesthesia maintenance, 2%~3% sevoflurane,fentanyl

Intervention Type DRUG

2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion

Group 3,dexmedetomidine 2μg.kg-1,1 milliliter

Patients will be assigned to receive intranasal dexmedetomidine( 2μg.kg-1 )1 milliliter

Group Type EXPERIMENTAL

Dexmedetomidine 2μg.kg-1,1 milliliter

Intervention Type DRUG

Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction

Anesthesia induction, 8% sevoflurane

Intervention Type DRUG

Inhalation induction with 8% sevoflurane

Anesthesia maintenance, 2%~3% sevoflurane,fentanyl

Intervention Type DRUG

2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Normal saline,1 milliliter

Normal saline,1 milliliter, 20 minutes before anaesthetic induction

Intervention Type DRUG

Dexmedetomidine 1 μg.kg-1,1 milliliter

Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction

Intervention Type DRUG

Dexmedetomidine 2μg.kg-1,1 milliliter

Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction

Intervention Type DRUG

Anesthesia induction, 8% sevoflurane

Inhalation induction with 8% sevoflurane

Intervention Type DRUG

Anesthesia maintenance, 2%~3% sevoflurane,fentanyl

2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent.
* Elective cleft lip and cleft palate repair surgery
* American Society of Anesthesiologists class I
* Aged between 6 months and 7 years old

Exclusion Criteria

* Suspected or confirmed difficult airway
* History of upper respiratory tract infection with 1 month
* Combined with congenital heart disease
* Allergic to investigational products or with other contraindication
* Growth retardation or dysgnosia
* Central nervous system disease
* Serious infection
* Serious heart,brain,liver,kidney, pulmonary, and endocrine disease
Minimum Eligible Age

6 Months

Maximum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xijing Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

wangqiang

department of anesthesijology

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Sedation wei

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.